公开(公告)号：US20210290710A1

公开(公告)日：2021-09-23

申请号：US17138610

申请日：2020-12-30

Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Inventor： I-Hong PAN ,  Kuei-Chang LI ,  Zong-Keng KUO ,  Chu-Hsun LU ,  Yen-Wu HSIEH ,  Shu-Fang WEN

IPC: A61K36/074 ,  A61K36/185 ,  A61K36/725 ,  A61K36/77 ,  A61K31/575 ,  A61P25/28 ,  A61P25/20 ,  A61P1/00

Abstract: A composition for modulating intestinal permeability and/or treating and/or preventing leaky gut related diseases including a Chinese herbal compound material or a Chinese herbal compound extract is provided. The Chinese herbal compound material includes Ganoderma, red jujube, longan and lotus seed. Moreover, the Chinese herbal compound extract includes a Ganoderma extract, a red jujube extract, a longan extract and a lotus seed extract.

公开(公告)号：US20170258865A1

公开(公告)日：2017-09-14

申请号：US15416391

申请日：2017-01-26

Applicant: Industrial Technology Research Institute

Inventor： Kuo-Kuei HUANG ,  I-Horng PAN ,  Ying-Fei TSAI ,  I-Huang LU ,  Chu-Hsun LU ,  Shu-Fang WEN ,  Zong-Keng KUO ,  Shu-Jiau CHIOU

IPC: A61K36/75 ,  A61K31/404 ,  A61K31/4015 ,  A61K31/366 ,  A61K31/37

Abstract: The present disclosure provides a pharmaceutical composition for treating or alleviating an autoimmune disease and/or complication thereof and/or nephritis, including: an effective amount of an extract of a plant belonging to Rutaceae as an effective ingredient for treating or alleviating the autoimmune disease and/or complication thereof and/or nephritis, wherein the autoimmune disease is selected from a group consisting of lupus erythematosus, psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, juvenile idiopathic arthritis, Crohn's disease and ulcerative colitis (UC).

公开(公告)号：US20240165181A1

公开(公告)日：2024-05-23

申请号：US18327583

申请日：2023-06-01

Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Inventor： I-Hong PAN ,  Kuei-Chang LI ,  Zong-Keng KUO ,  Chu-Hsun LU ,  Yen-Wu HSIEH ,  Shu-Fang WEN

IPC: A61K36/074 ,  A61K31/575 ,  A61K36/185 ,  A61K36/725 ,  A61K36/77 ,  A61P1/00 ,  A61P25/20 ,  A61P25/28

CPC classification number: A61K36/074 ,  A61K31/575 ,  A61K36/185 ,  A61K36/725 ,  A61K36/77 ,  A61P1/00 ,  A61P25/20 ,  A61P25/28

Abstract: A composition for inhibiting intestinal permeability, treating leaky gut related diseases and/or preventing leaky gut related diseases including a Chinese herbal compound material or a Chinese herbal compound extract is provided. The Chinese herbal compound material includes Ganoderma, red jujube, longan and lotus seed. Moreover, the Chinese herbal compound extract includes a Ganoderma extract, a red jujube extract, a longan extract and a lotus seed extract.

公开(公告)号：US20140170250A1

公开(公告)日：2014-06-19

申请号：US14133213

申请日：2013-12-18

Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Inventor： I-Horng PAN ,  Hsin-Jan YAO ,  Mei-Wei LIN ,  I-Huang LU ,  Hsin-Chieh WU ,  Hsiang-Wen TSENG ,  Ching-Huai KO ,  Chun-Chung WANG ,  Zong-Keng KUO ,  Shyh-Horng LIN ,  Yi-Cheng CHENG ,  Tien-Soung TONG

IPC: A61K36/14 ,  A61K31/357

CPC classification number: A61K31/365 ,  A61K31/7048 ,  A61K36/14 ,  A61K2300/00

Abstract: The disclosure provides a pharmaceutical composition for inhibiting angiogenesis, including an effective amount of an extract of Juniperus chinensis or an effective amount of a lignan as an effective ingredient. The pharmaceutical composition may further include a pharmaceutically acceptable carrier or salt. The disclosure also provides a method for inhibiting angiogenesis, including administering an effective amount of an extract of Juniperus chinensis or an effective amount of a lignan as an effective ingredient for inhibiting angiogenesis to a subject in need thereof.

Abstract translation: 本公开内容提供了用于抑制血管生成的药物组合物，包括有效量的桧属提取物或有效量的木酚素作为有效成分。 药物组合物还可以包括药学上可接受的载体或盐。 本公开还提供了抑制血管发生的方法，包括给予有效量的桧属提取物或有效量的木脂素作为有效成分，用于抑制有需要的受试者的血管生成。

公开(公告)号：US20220249395A1

公开(公告)日：2022-08-11

申请号：US17727301

申请日：2022-04-22

Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Inventor： Kuo-Kuei HUANG ,  I-Hong PAN ,  Shu-Fang WEN ,  Meng-Nan LIN ,  I-Huang LU ,  Zong-Keng KUO ,  Chu-Hsun LU ,  Tze-Chung LEE ,  Ya-Yan YANG ,  Jia-Horng LIAW ,  Pei-Hsin LIN

IPC: A61K31/047 ,  A61K31/215 ,  A61K31/335 ,  A61K9/50 ,  A61K31/352 ,  A61K9/00 ,  A61K31/045 ,  A61P37/00 ,  A61P25/28 ,  A61K9/08 ,  A61K9/14 ,  A61K31/075 ,  A61K31/122 ,  A61K31/222 ,  A61K31/343 ,  A61K47/02 ,  A61K47/26 ,  A61K47/34 ,  A61K47/38 ,  A61K47/40

Abstract: A method for treating an autoimmune neurological disease and/or a neurodegenerative disease is provided. The method includes administering an effective amount of at least one compound having Formula (I), Formula (II) or Formula (III), or its geometric isomer, enantiomer or diastereomer to a subject in need thereof: wherein is a single or double bond, X is NCH3 or CH2, Y is null, O or N, Z is O or N, R1 is H, OH, and R2 is null, H, C1-C8 alkyl, —(C═O)-alkyl, —(C═O)-aryl, —(C═O)-alkyl-aryl, —(C═O)-heteroaryl, cycloalkyl or heterocycloalkyl, which optionally substituted by one or more of —OH, —NO2, —NH2, —NR3R4, carbonyl, alkoxyl, alkyl or —OCF3, wherein R3 and R4 independently are H, alkyl, O2CH3, —(C═O)—CH3 or (C═O)—NH2.

公开(公告)号：US20210015882A1

公开(公告)日：2021-01-21

申请号：US17036985

申请日：2020-09-29

Applicant: Industrial Technology Research Institute

Inventor： Kuo-Kuei HUANG ,  I-Horng PAN ,  Ying-Fei TSAI ,  I-Huang LU ,  Chu-Hsun LU ,  Shu-Fang WEN ,  Zong-Keng KUO ,  Shu-Jiau CHIOU

IPC: A61K36/75 ,  A61K31/395 ,  A61K31/366 ,  A61K31/37 ,  A61K31/4015 ,  A61K31/404

Abstract: The present disclosure provides a pharmaceutical composition for treating or alleviating an autoimmune disease and/or complication thereof and/or nephritis, including: an effective amount of an extract of a plant belonging to Rutaceae as an effective ingredient for treating or alleviating the autoimmune disease and/or complication thereof and/or nephritis, wherein the autoimmune disease is selected from a group consisting of lupus erythematosus, psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, juvenile idiopathic arthritis, Crohn's disease and ulcerative colitis (UC).

公开(公告)号：US20190000776A1

公开(公告)日：2019-01-03

申请号：US16023940

申请日：2018-06-29

Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Inventor： Kuo-Kuei HUANG ,  I-Hong PAN ,  Shu-Fang WEN ,  Meng-Nan LIN ,  I-Huang LU ,  Zong-Keng KUO ,  Chu-Hsun LU ,  Tze-Chung LEE ,  Ya-Yan YANG ,  Jia-Horng LIAW

IPC: A61K31/047 ,  A61K31/222 ,  A61K31/075 ,  A61K31/122 ,  A61K31/343 ,  A61K9/14 ,  A61K9/08 ,  A61K47/02 ,  A61K47/26 ,  A61K47/34 ,  A61K47/38 ,  A61K47/40 ,  A61P25/28 ,  A61P37/00

Abstract: A method for treating an autoimmune neurological disease and/or a neurodegenerative disease is provided. The method includes administering an effective amount of at least one compound having Formula (I), Formula (II) or Formula (III), or its geometric isomer, enantiomer or diastereomer to a subject in need thereof: wherein is a single or double bond, X is NCH3 or CH2, Y is null, O or N, R1 is H, OH, and R2 is null, H, C1-C8 alkyl, —(C═O)-alkyl, —(C═O)-aryl, —(C═O)-alkyl-aryl, —(C═O)-heteroaryl, cycloalkyl or heterocycloalkyl, which optionally substituted by one or more of —OH, —NO2, —NH2, —NR3R4, carbonyl, alkoxyl, alkyl or —OCF3, wherein R3 and R4 independently are H, alkyl, —SO2CH3, —(C═O)—CH3 or —(C═O)—NH2.

公开(公告)号：US20160008319A1

公开(公告)日：2016-01-14

申请号：US14864203

申请日：2015-09-24

Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Inventor： I-Horng PAN ,  Hsin-Jan YAO ,  Mei-Wei LIN ,  I-Huang LU ,  Hsin-Chieh WU ,  Hsiang-Wen TSENG ,  Ching-Huai KO ,  Chun-Chung WANG ,  Zong-Keng KUO ,  Shyh-Horng LIN ,  Yi-Cheng CHENG ,  Tien-Soung TONG

IPC: A61K31/365 ,  A61K31/7048

CPC classification number: A61K31/365 ,  A61K31/7048 ,  A61K36/14 ,  A61K2300/00

Abstract: The disclosure provides a pharmaceutical composition for inhibiting angiogenesis, including an effective amount of a lignan as an effective ingredient. The pharmaceutical composition may further include a pharmaceutically acceptable carrier or salt. The disclosure also provides a method for inhibiting angiogenesis, including administering an effective amount of a lignan as an effective ingredient for inhibiting angiogenesis to a subject in need thereof.

Abstract translation: 本公开提供了用于抑制血管发生的药物组合物，包括有效量的木脂素作为有效成分。 药物组合物还可以包括药学上可接受的载体或盐。 本公开还提供了一种抑制血管生成的方法，包括给予有效量的木脂素作为有效成分，用于抑制有需要的受试者的血管生成。